natgillin/translations-raw huggingface dataset:
In Study CMEK162B2301-Part 2, in the Combo 300 arm, fatigue was observed in 33.5% (86/257) of patients with 1.6% (4/257) Grade 3-4 events. 
V 2. delu študije CMEK162B2301 so pri bolnikih, zdravljenih v okviru kombinacije 300, utrujenost opazili pri 33,5 % (86/257) bolnikov, z dogodki 3.-4. stopnje pri 1,6 % (4/257) bolnikov.
Cutaneous reactions • Grade2 
Kožne reakcije • 2. stopnja
Dose modification was reported in 0.7 % (2/274) of patients. 
0,7 % (2/274) bolnikov so poročali o spremembi odmerka.
The safety of binimetinib (45 mg orally twice daily) in combination with encorafenib (450 mg orally once daily) (hereafter referred to as Combo 450) was evaluated in 274 patients with BRAF V600 mutant unresectable or metastatic melanoma, based on two Phase II studies (CMEK162X2110 and CLGX818X2109) and one Phase III study (CMEK162B2301, Part 1) (hereafter referred to as the pooled Combo 450 population). 
Varnost binimetiniba (peroralno 45 mg dvakrat dnevno) v kombinaciji z enkorafenibom (peroralno 450 mg enkrat dnevno) (v nadaljevanju kombinacija 450) so ovrednotili pri 274 bolnikih z neresektabilnim ali metastatskim melanomom z mutacijo V600 gena BRAF na podlagi dveh študij II.
In Study CMEK162B2301-Part 2, in the Combo 300 arm, nausea was observed in 27.2% (70/257) of patients and was Grade 3 in 1.6% (4/257) of patients. 
V 2. delu študije CMEK162B2301 so pri bolnikih, zdravljenih v okviru kombinacije 300, slabost opazili pri 27,2 % (70/257) bolnikov, pri 1,6 % (4/257) bolnikov je bila 3. stopnje.
• eye problems including glaucoma or increased pressure in your eyes 
• težave s krvavitvami ali če jemljete zdravila, ki lahko povzročijo krvavitve, • težave z očmi, vključno z glavkomom ali povišanim tlakom v očeh,
In Study CMEK162B2301-Part 2, in the Combo 300 arm, RPED was observed in 12.5% (32/257) of patients with 0.4% (1/257) Grade 4 event. 
V 2. delu študije CMEK162B2301 so RPED pri bolnikih, zdravljenih v okviru kombinacije 300, opazili pri 12,5 % (32/257) bolnikov, pri 0,4 % (1/257) bolnikov je bila 4. stopnje.
Cutaneous malignancies 
Kožne malignosti
Binimetinib inhibits activation of MEK by BRAF and inhibits MEK kinase activity. 
Binimetinib zavira aktivacijo proteinov MEK, ki jo sproži
• If resolved within 4 weeks, binimetinib should be resumed at a reduced dose, or 
• Če se v 4 tednih stanje izboljša, je treba nadaljevati z zmanjšanim odmerkom binimetiniba, ali • vnašanje binimetiniba je treba trajno prekiniti.
Facial paresis was reported when binimetinib was used in combination with encorafenib (see section 4.8 of encorafenib SmPC). 
O parezi obraza so poročali, ko se je binimetinib uporabljal v kombinaciji z enkorafenibom (glejte poglavje 4.8 Povzetka glavnih značilnosti zdravila enkorafenib).
HRa (95 % CI) (vs Vem) p-value (stratified log-rank) HRa (95 % CI) (vs. Enco 300) p-value (stratified log-rank) 
HRa (95-odstotni IZ) (proti Enko 300) p-vrednost (stratificirani log-rang test)
Binimetinib should be withheld. 
Vnašanje binimetiniba je treba prekiniti.
In Study CMEK162B2301-Part 2, in the Combo 300 arm, haemorrhagic events were observed in 6.6% (17/257) of patients and were Grade 3-4 in 1.6% (4/257) of patients. 
V 2. delu študije CMEK162B2301 so pri bolnikih, zdravljenih v okviru kombinacije 300, krvavitve opazili pri 6,6 % (17/257) bolnikov, ki so bile pri 1,6 % (4/257) bolnikov 3-4. stopnje.
Blood creatinine elevation and renal failure occurred when binimetinib was used in combination with encorafenib (see section 4.8 of encorafenib SmPC). 
Pri jemanju binimetiniba v kombinaciji z enkorafenibom sta se pojavila dvig kreatinina v krvi in odpoved ledvic (glejte poglavje 4.8 Povzetka glavnih značilnosti zdravila enkorafenib).
In patients treated with Combo 450, dermatitis acneiform occurred in 4.4 % (12/274) of patients, was Grade 1 and 2 and no event led to treatment discontinuation. 
Pri bolnikih, zdravljenih s kombinacijo 450, se je akneiformni dermatitis pojavil pri 4,4 % (12/274) bolnikov.
Patients at risk COMBO 450 
ki so se zdravili s kombinacijo 450.
Dizziness* 
Vrtoglavica*
• If improved to Grade 0 or 1, binimetinib should be resumed at reduced dose, or 
• Če se stanje izboljša do stopnje 0 ali 1. stopnje, je treba nadaljevati z zmanjšanim odmerkom binimetiniba, ali
• If improved to Grade 0 or 1 or baseline level, binimetinib should be resumed at reduced dose, or 
• Če se stanje izboljša do stopnje 0 ali 1. stopnje oziroma do izhodiščne vrednosti, je treba nadaljevati z zmanjšanim odmerkom binimetiniba, ali
Pruritus* 
Driska*
Binimetinib should be maintained. 
Vnašanje binimetiniba je treba nadaljevati.
Abdominal pain* 
Bolečine v trebuhu*
Haemorrhagic events led to discontinuation of treatment in 1.1 % (3/274) of patients. 
Zdravljenje je bilo zaradi krvavitev treba prekiniti pri 1,1 % (3/274) bolnikov.
Treatment Median OS (months) 
Pri bolnikih z zmerno (Child
In patients treated with Combo 450, VTE occurred in 4.7 % (13/274) of patients, including 2.2 % (6/274) of patients who developed pulmonary embolism. 
Venski tromboembolizem Pri bolnikih, zdravljenih s kombinacijo 450, se je VTE pojavil pri 4,7 % (13/274) bolnikov, vključno z
Binimetinib should be used with caution in patients who are at risk for, or who have a history of VTE. 
Pri bolnikih z anamnezo VTE ali s tveganjem za VTE je treba binimetinib uporabljati previdno.
• Recurrent Grade 3 adverse reactions 
• Ponovni pojav neželenih učinkov
• Grade 3 or grade 4 (CK > 5x ULN) with muscle symptoms or renal impairment 
• 3. ali 4. stopnja (CK > 5-kratnika
CuSCC was reported when binimetinib was used in combination with encorafenib (see section 4.8 of encorafenib SmPC). 
Pri jemanju binimetiniba v kombinaciji z enkorafenibom so poročali o pojavu ploščatoceličnega karcinoma kože (CuSCC) (glejte poglavje 4.8 Povzetka glavnih značilnosti zdravila enkorafenib).
Gamma-glutamyl transferase increased* 
Zvišana vrednost gamaglutamiltransferaze*
Probability of Overall Survival (%) 
Število dogodkov (%)
Non-cutaneous malignancies 
Nekožne malignosti
Pancreatitis was reported when binimetinib was used in combination with encorafenib (see section 4.8 of encorafenib SmPC). 
Pri jemanju binimetiniba v kombinaciji z enkorafenibom so poročali o pojavu pankreatitisa (glejte poglavje 4.8 Povzetka glavnih značilnosti zdravila enkorafenib).
• eye pain, swelling or redness 
• bolečin v očeh, zatekanja ali rdečih oči.
Or, binimetinib should be permanently discontinued binimetinib. 
Ali trajno prekiniti vnašanje binimetiniba.
• swelling in the legs 
• Zmanjšanje LVEF
Haemorrhage 
Krvavitvee
Further information on Zelboraf can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Nadaljnje informacije za zdravilo Zelboraf so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Each dose can be taken with or without food, but Zelboraf should be taken in the same way day-to-day. 
Vsak odmerek se lahko vzame s hrano ali brez nje, vendar pa je treba zdravilo Zelboraf vedno vzeti na enak način.
The European Medicines Agency decided that Zelboraf's benefits are greater than its risks and it can be authorised for use in the EU. 
Evropska agencija za zdravila je zaključila, da so koristi zdravila Zelboraf večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
Zelboraf received a marketing authorisation valid throughout the EU on 17 February 2012. 
Za zdravilo Zelboraf je bilo 17. februarja 2012 izdano dovoljenje za promet, veljavno po vsej EU.
What measures are being taken to ensure the safe and effective use of Zelboraf? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Zelboraf?
Zelboraf is available as tablets (240 mg). 
Zdravilo Zelboraf je na voljo v obliki tablet (240 mg).
As for all medicines, data on the use of Zelboraf are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Zelboraf stalno spremljajo.
The main measures of effectiveness were how long the patients lived (overall survival) and how long they lived without their disease getting worse (progression-free survival). 
Glavni merili učinkovitosti sta bili čas preživetja (celokupno preživetje) in čas preživetja brez poslabšanja bolezni (preživetje brez napredovanja bolezni).
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Zelboraf have been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Zelboraf upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
Other information about Zelboraf 
Druge informacije o zdravilu Zelboraf
What benefits of Zelboraf have been shown in studies? 
Kakšne koristi zdravila Zelboraf so se pokazale v študijah?
What is Zelboraf and what is it used for? 
Kaj je zdravilo Zelboraf in za kaj se uporablja?
Zelboraf was shown to be effective at prolonging patients' lives and delaying the worsening of the disease. 
Zdravilo Zelboraf je bilo učinkovito pri podaljšanju življenja bolnikov in odložitvi poslabšanja bolezni.
The most common side effects with Zelboraf (which may affect more than 3 in 10 patients) include arthralgia (joint pain), tiredness, rash, photosensitivity reaction (sunburn-like reactions following exposure to light), nausea and vomiting (feeling sick and being sick), alopecia (hair loss), diarrhoea, headache, pruritus (itching), skin papilloma (warts) and hyperkeratosis (thickening and toughening of the skin). 
Najpogostejši neželeni učinki zdravila Zelboraf (ki se lahko pojavijo pri več kot 3 od 10 bolnikov) so artralgija (bolečine v sklepih), utrujenost, izpuščaji, fotosenzibilna reakcija (reakcije, podobne sončnim opeklinam, ki so posledica izpostavljenosti svetlobi), navzeja (siljenje na bruhanje) in bruhanje, alopecija (izpadanje las), driska, glavobol, pruritus (srbenje), papilom na koži (bradavice) in hiperkeratoza (zadebelitev in otrditev kože).
Why is Zelboraf authorised in the EU? 
Zakaj je bilo zdravilo Zelboraf odobreno v EU?
The Agency considered the side effects to be manageable and included recommendations for doctors to help reduce the risks in the product information. 
Agencija je menila, da so neželeni učinki obvladljivi in v informacije o zdravilu dodala priporočila za zdravnike, ki naj bi prispevala k zmanjšanju tveganj.
Side effects reported with Zelboraf are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Zelboraf, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
Zelboraf can only be obtained with a prescription and treatment should be started and supervised by a specialist doctor experienced in treating cancer. 
Predpisovanje in izdaja zdravila Zelboraf je le na recept, zdravljenje pa mora uvesti in nadzorovati zdravnik specialist, ki ima izkušnje z zdravljenjem raka.
An overview of Zelboraf and why it is authorised in the EU 
Pregled zdravila Zelboraf in zakaj je odobreno v EU
Treatment should be continued until the disease worsens or the side effects become too severe. 
Z zdravljenjem je treba nadaljevati, dokler se bolezen ne poslabša ali dokler neželeni učinki ne postanejo prehudi.
What are the risks associated with Zelboraf? 
Kakšna tveganja so povezana z zdravilom Zelboraf?
For more information about using Zelboraf, see the package leaflet or contact your doctor or pharmacist. 
Za več informacij glede uporabe zdravila Zelboraf glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
With regard to its risks, in the main study around half of the patients taking Zelboraf experienced a severe side effect and about one fifth developed cutaneous squamous cell carcinoma. 
Glede z njim povezanih tveganj se je v glavni študiji pri približno polovici bolnikov, ki so jemali zdravilo Zelboraf, pojavil resen neželeni učinek, približno pri eni petini pa se je razvil ploščatocelični karcinom kože.
The first dose is taken in the morning and the second dose in the evening around 12 hours later. 
Priporočeni odmerek je 960 mg (štiri tablete) dvakrat na dan. Prvi odmerek je treba vzeti zjutraj, drugi odmerek pa zvečer, približno 12 ur pozneje.
Zelboraf is a cancer medicine used to treat adults with melanoma (a type of skin cancer) that has spread to other parts of the body or cannot be surgically removed. 
Zelboraf je zdravilo za zdravljenje raka, ki se uporablja za zdravljenje odraslih z melanomom (vrsto kožnega raka), ki se je razširil na druge dele telesa ali ga ni mogoče kirurško odstraniti.
Zelboraf is only for patients whose melanoma tumour cells have a specific mutation (genetic change) called ‘BRAF V600'. 
Zdravilo Zelboraf se uporablja samo za bolnike, pri katerih imajo tumorske celice melanoma posebno mutacijo (gensko spremembo), imenovano „BRAF V600“.
The most common serious side effects include another type of skin cancer called ‘cutaneous squamous cell carcinoma', which is commonly treated by local surgery, keratoacanthoma (benign skin tumour), rash, arthralgia and change in liver test results (increased gamma-glutamyltransferase [GGT]). 
Najpogostejši resni neželeni učinki so druga vrsta kožnega raka, imenovana ploščatocelični karcinom kože, ki se uspešno zdravi z lokalno operacijo, keratoakantom (benigni kožni tumor), izpuščaji, artralgija in spremembe v izvidih jetrnih testov (zvišanje gama-glutamiltransferaze [GGT]).
The Agency noted that Zelboraf had been convincingly shown to improve overall survival and to delay the worsening of ‘BRAF V600 positive' melanoma which has spread or cannot be surgically removed. 
Agencija ugotavlja, da je zdravilo Zelboraf prepričljivo dokazalo, da izboljšuje celokupno preživetje in odlaga poslabšanje melanoma s pozitivno BRAF V600 mutacijo, ki se je razširil ali ga ni mogoče kirurško odstraniti.
Before starting treatment a test must be carried out to make sure that the patient's tumours have the BRAF V600 mutation. 
Pred začetkom zdravljenja je treba narediti test, ki potrdi mutacijo BRAF V600 v tumorskih celicah bolnika.
For the full list of side effects and restrictions with Zelboraf, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Zelboraf glejte navodilo za uporabo.
In melanoma tumours with the BRAF V600 mutation, an abnormal form of BRAF is present which plays a role in the development of the cancer by allowing uncontrolled division of the tumour cells. 
V tumorjih melanoma z mutacijo BRAF V600 je prisotna neobičajna oblika beljakovine BRAF, ki vpliva na razvoj raka tako, da omogoča nenadzorovano deljenje tumorskih celic.
The study showed that patients taking Zelboraf lived on average for 13.2 months compared with 9.9 months for patients on dacarbazine, and it took on average 5.3 months for the disease to worsen in the Zelboraf group compared with 1.6 months in the dacarbazine group. 
Študija je pokazala, da so bolniki, ki so jemali zdravilo Zelboraf, v povprečju živeli 13,2 meseca, medtem ko so bolniki, ki so jemali dakarbazin, živeli 9,9 meseca.
The active substance in Zelboraf, vemurafenib, is an inhibitor of BRAF, a protein involved in stimulating cell division. 
Učinkovina v zdravilu Zelboraf, vemurafenib, je zaviralec BRAF, beljakovine, ki sodeluje pri spodbujanju delitve celic.
By blocking the action of the abnormal BRAF, Zelboraf helps to slow down the growth and spread of the cancer. 
Zdravilo Zelboraf z zaviranjem delovanja neobičajne beljakovine BRAF prispeva k upočasnitvi rasti in širjenja raka.
Patients were to receive either medicine until their disease got worse or their 
Bolniki so posamezno zdravilo prejemali, dokler se bolezen ni poslabšala ali je zdravljenje zanje postalo preveč toksično.
How is Zelboraf used? 
Kako se zdravilo Zelboraf uporablja?
How does Zelboraf work? 
Kako zdravilo Zelboraf deluje?
Zelboraf was compared with the cancer medicine dacarbazine in a main study involving 675 patients with melanoma containing the BRAF V600 mutation whose tumours had spread or could not be surgically removed. 
Zdravilo Zelboraf so v glavni študiji, ki je vključevala 675 bolnikov z melanomom, ki je vseboval mutacijo BRAF V600, pri katerih se je tumor razširil ali ga ni bilo mogoče kirurško odstraniti, primerjali z zdravilom proti raku dakarbazin.
Zelboraf contains the active substance vemurafenib. 
Vsebuje učinkovino vemurafenib.
The preliminary review was concluded on 8th of February 2018. 
Začasni pregled je bil zaključen 8. februarja 2018.
Three out of those four cases of serious liver injury were reported to the competent authorities before November 2017. 
Trije od teh štirih primerov resne poškodbe jeter so bili pristojnim organom sporočeni pred novembrom 2017.
Nevertheless, the review of cumulatively reported post-marketing cases does not allow a firm conclusion at this stage. 
Pregled kumulativno prijavljenih primerov iz obdobja trženja v tej fazi kljub temu ne omogoča trdnega zaključka.
Patients overcoming such threshold should be closely monitored after discontinuation of the treatment. 
Bolnike, ki presežejo ta prag, je treba po opustitvi zdravljenja natančno spremljati.
Acknowledging the uncertainty regarding background incidence and the information in the reported cases, the seriousness of the reported cases raises concern. 
Ob priznavanju nejasnosti o osnovni incidenci in informacij v primerih, o katerih so poročali, vzbuja zaskrbljenost resnost prijavljenih primerov.
The adequacy of these provisional measures will be reviewed as part of the ongoing Article 20. 
Presoja ustreznosti teh začasnih ukrepov bo opravljena kot del potekajočega postopka iz člena 20.
An in depth assessment is needed to firmly establish factors that may have caused the reported serious hepatic injuries. 
Potrebna je tudi poglobljena ocena, s katero bi trdno določili dejavnike, ki so lahko povzročili resne poškodbe jeter, o katerih so poročali.
However, there are a few cases of serious hepatic injury, where no other obvious explanation has been identified, despite uncertainty in relation to possible confounding. 
Vendarle pa obstaja nekaj primerov resnih poškodb jeter, pri katerih kljub nejasnosti v povezavi z možnimi zavajajočimi dejavniki ni bilo mogoče prepoznati nobene očitne razlage.
It is therefore too early to conclude that the risk of hepatotoxicity is associated with the use of Esmya for all cases. 
Zato je prezgodaj za zaključek, da je tveganje za hepatotoksičnost povezano z uporabo zdravila Esmya pri vseh primerih.
Although firm conclusions cannot be drawn that these cases were caused by Esmya, the available data raise serious concerns. 
Čeprav ni mogoče sprejeti trdnega zaključka, da je te primere povzročilo zdravilo Esmya, razpoložljivi podatki vzbujajo resne pomisleke.
A fourth case of hepatic liver failure leading to transplantation was reported on 30th of January 2018. 
Četrti primer odpovedi jeter, ki je privedla do presaditve, je bil sporočen 30. januarja 2018.
On 30 November 2017 the European Commission triggered a procedure under Article 20 of Regulation (EC) No 726/2004 resulting from pharmacovigilance data, and requested the PRAC to assess the impact of the above concerns on the benefit-risk balance of Esmya and to issue a recommendation on whether the relevant marketing authorisations should be maintained, varied, suspended or revoked. 
Evropska komisija je zato 30. novembra 2017 na podlagi farmakovigilančnih podatkov sprožila postopek v skladu s členom 20 Uredbe (ES) št. 726/2004 in odbor PRAC zaprosila, naj oceni vpliv zgornjih pomislekov na razmerje med tveganji in koristmi zdravila Esmya ter izda priporočilo o tem, ali naj se ustrezna dovoljenja za promet z zdravilom ohranijo, spremenijo, začasno umaknejo ali odvzamejo.
• The PRAC considered the procedure under Article 20 of Regulation (EC) No 726/2004 resulting from pharmacovigilance data for Esmya (Ulipristal acetate), in particular the need for provisional measures in accordance with Article 20(3) of Regulation (EC) N0 726/2004. 
• Odbor PRAC je upošteval postopek iz člena 20 Uredbe (ES) št. 726/2004, ki je bil sprožen na podlagi farmakovigilančnih podatkov za zdravilo Esmya (ulipristalacetat), zlasti zaradi potrebe po uvedbi začasnih ukrepov v skladu s členom 20(3) Uredbe (ES) št. 726/2004.
Even though it is unclear at this stage whether monitoring of transaminases would necessarily prevent further severe cases, liver function monitoring is expected to be an important measure to detect liver injury during treatment, and likely reduce the incidence of severe cases. 
Čeprav v tej fazi ni jasno, ali bi spremljanje transaminaz nedvomno preprečilo nadaljnje hude primere, se pričakuje, da bo spremljanje delovanja jeter pomembno pripomoglo k prepoznavi poškodbe jeter med zdravljenjem in verjetno zmanjšalo incidenco hudih primerov.
Liver monitoring should also be performed up to four weeks after the discontinuation of the treatment. 
Poleg tega je treba spremljanje delovanja jeter nadaljevati do štiri tedne po prenehanju zdravljenja.
In addition to these, a preliminary assessment of a recently reported case of liver transplantation with fatal outcome was performed. 
Poleg tega je bila opravljena preliminarna ocena nedavno prijavljenega primera presaditve jeter s smrtnim izidom.
The absence of findings in clinical trials has to be interpreted with caution as abnormal values of ALT/AST was an exclusion criterion as per protocols 
Odsotnost izsledkov v kliničnih preskušanjih je treba razlagati previdno, saj so bile nenormalne vrednosti encimov ALT/AST po protokolih izključitveno merilo.
The Committee, as a consequence, recommends the variations of the terms of the marketing authorisation for Esmya. 
Odbor posledično priporoča spremembo pogojev dovoljenja za promet z zdravilom Esmya.
These provisional measures are without prejudice to the outcome of the ongoing review under Article 20 procedure. 
Ti začasni ukrepi ne posegajo v izid potekajočega pregleda v okviru postopka v skladu s členom 20.
Patients exhibiting signs and symptoms suggestive of liver injury should promptly contact a healthcare professional. 
Bolniki z znaki in simptomi, ki kažejo na poškodbe jeter, morajo nemudoma stopiti v stik z zdravstvenim delavcem.
Taking into account this new case and the totality of the reported cases, a preliminary review and assessment of all the data available was performed by PRAC, to consider if provisional measures were needed while the issue is being furtherly reviewed. 
Ob upoštevanju tega novega primera in skupnega števila sporočenih primerov je odbor PRAC opravil predhodni pregled in oceno vseh razpoložljivih podatkov, da bi ocenil, ali so med nadaljnjim pregledom zadeve potrebni začasni ukrepi.
In addition, PRAC considers that involvement of Esmya in at least two of the four transplantation cases reported and in two additional less serious cases, is at least plausible. 
Odbor PRAC poleg tega meni, da je povezava z zdravilom Esmya in vsaj dvema od štirih prijavljenih primerov presaditve in dvema dodatnim manj resnima primeroma verjetna.
• Furthermore, PRAC recommended that a healthcare professional communication should be disseminated to inform healthcare professionals about the precautionary measures, awaiting the outcome of the full review of Esmya. 
• Odbor PRAC je poleg tega priporočil, da se zdravstvenim delavcem sporočijo informacije o previdnostnih ukrepih med čakanjem na izid celovitega pregleda zdravila Esmya.
• The PRAC recommends that no new patients should be treated with the medicinal product while the review is ongoing. 
• Odbor PRAC priporoča, da se med potekom pregleda z zdravilom ne zdravi noben nov bolnik.
In addition, several other cases of hepatic impairment associated with the use of the product were reported. 
Poleg tega so poročali o več drugih primerih okvar jeter, povezanih z uporabo tega zdravila.